Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
3,833
Views
3
CrossRef citations to date
0
Altmetric
COVID-19
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
Adrian Kilcoynea Humanigen Inc, Burlingame, CA, United StatesCorrespondence[email protected]
, Edward Jordana Humanigen Inc, Burlingame, CA, United States
, Allen Zhoub EVERSANA, Burlington, ON, Canada
, Kimberly Thomasb EVERSANA, Burlington, ON, Canada
, Alicia N. Pepperb EVERSANA, Burlington, ON, Canada
, Dale Chappella Humanigen Inc, Burlingame, CA, United States
, Miyuru Amarapalaa Humanigen Inc, Burlingame, CA, United States
, Avery Hughesb EVERSANA, Burlington, ON, Canada
& Melissa Thompsonb EVERSANA, Burlington, ON, Canada
show all
Pages 160-171
|
Received 08 Oct 2021, Accepted 13 Jan 2022, Published online: 10 Feb 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.